ATRX loss is also frequently observed in H3.3-mutated gliomas (G34R/V and K27M), including nearly 100% of hemispheric G34R/V-mutant gliomas and approximately 30% of midline diffuse gliomas [15]. Here, ATRX is linked to central nervous system cancer.